Filing Flows › Charles River Laboratories International (CRL) › Q3 2026 › vs Q3 2025
Charles River Laboratories International (CRL) Q3 2026 vs Q3 2025 (year over year)
Charles River Laboratories International's revenue fell $22.1M (-2%) from $1.0B in Q3 2025 to $983M in Q3 2026. The biggest changes: Manufacturing −$11.8M (-6%); RMS −$5.9M (-3%); DSA −$4.4M (-0.7%). Operating margin 20.6% against 13.3% (+7.3 pts).
Charles River Laboratories International, Q3 2026: revenue $983M (-2% year over year), operating margin 20.6%, net earnings $333M, operating cash flow $254M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 20.6% | 13.3% | +7.3 pts |
| Net margin | 33.9% | 5.4% | +28.5 pts |
| Free cash flow margin | 21.1% | 17.7% | +3.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| DSA | $596M | $601M | −$4.4M | -0.7% |
| RMS | $208M | $213M | −$5.9M | -3% |
| Manufacturing | $179M | $191M | −$11.8M | -6% |
| Revenue | $983M | $1.0B | −$22.1M | -2% |
| Operating profit | $203M | $134M | $68.8M | +51% |
| Costs & expenses | $780M | $871M | −$91.0M | -10% |
| Pre-tax earnings | $171M | $87.2M | $83.5M | +96% |
| Other expense, net | $32.0M | $46.6M | −$14.6M | -31% |
| SG&A | $141M | $178M | −$37.0M | -21% |
| Other operating costs | $640M | $693M | −$54.0M | -8% |
| Income tax benefit | $164M | −$31.6M | $195M | — |
| Net earnings | $333M | $54.4M | $279M | +512% |
| Minority interests | $1.4M | $1.1M | $243K | +21% |
| Depreciation & amortization | $72.3M | $85.2M | −$12.9M | -15% |
| Share-based compensation | $20.8M | $23.3M | −$2.5M | -11% |
| Working capital & other | $172M | −$51.0M | $223M | — |
| Operating cash flow | $254M | $214M | $40.3M | +19% |
| Free cash flow (OCF − capex) | $207M | $178M | $29.0M | +16% |
| Capital expenditures | $46.8M | $35.6M | $11.2M | +32% |
Questions
How much did Charles River Laboratories International's revenue grow year over year in Q3 2026?
Charles River Laboratories International's revenue fell $22.1M (-2%) from $1.0B in Q3 2025 to $983M in Q3 2026.
What drove Charles River Laboratories International's revenue change in Q3 2026?
Manufacturing −$11.8M (-6%); RMS −$5.9M (-3%); DSA −$4.4M (-0.7%).